Does the media prefer LGND or ADMA?

In the previous week, ADMA Biologics had 31 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 43 mentions for ADMA Biologics and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat ADMA Biologics' score of 0.10 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADMA Biologics 3 Very Positive mention(s) 0 Positive mention(s) 39 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ANIP or LGND?

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 12 articles in the media. ANI Pharmaceuticals' average media sentiment score of 1.21 beat Ligand Pharmaceuticals' score of 1.07 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INCY or LGND?

In the previous week, Incyte had 26 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 38 mentions for Incyte and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat Incyte's score of 1.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 21 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor UTHR or LGND?

In the previous week, United Therapeutics had 20 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 32 mentions for United Therapeutics and 12 mentions for Ligand Pharmaceuticals. United Therapeutics' average media sentiment score of 1.25 beat Ligand Pharmaceuticals' score of 1.07 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 23 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LGND or NBIX?

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat Neurocrine Biosciences' score of 1.04 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 11 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ligand Pharmaceuticals (LGND) Competitors

$296.28 -1.22 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$296.09 -0.19 (-0.06%)

As of 04:49 PM Eastern

Compare

LGND vs. ADMA, ANIP, INCY, UTHR, and NBIX

Should you buy Ligand Pharmaceuticals stock or one of its competitors? MarketBeat compares Ligand Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Incyte (INCY), United Therapeutics (UTHR), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

In the previous week, ADMA Biologics had 31 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 43 mentions for ADMA Biologics and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat ADMA Biologics' score of 0.10 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	3 Very Positive mention(s)	0 Positive mention(s)	39 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ligand Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, ADMA Biologics has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 3.9% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Ligand Pharmaceuticals has a net margin of 55.95% compared to ADMA Biologics' net margin of 32.43%. ADMA Biologics' return on equity of 39.98% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
ADMA Biologics	32.43%	39.98%	28.08%

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. ADMA Biologics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$274.48M	21.63	$124.45M	$7.37	40.20
ADMA Biologics	$510.17M	3.99	$146.93M	$0.68	12.93

Ligand Pharmaceuticals currently has a consensus target price of $319.00, indicating a potential upside of 7.67%. ADMA Biologics has a consensus target price of $18.67, indicating a potential upside of 112.36%. Given ADMA Biologics' higher possible upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Ligand Pharmaceuticals beats ADMA Biologics on 10 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

In the previous week, ANI Pharmaceuticals and ANI Pharmaceuticals both had 12 articles in the media. ANI Pharmaceuticals' average media sentiment score of 1.21 beat Ligand Pharmaceuticals' score of 1.07 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has lower revenue, but higher earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$923.71M	2.00	$78.34M	$3.95	20.52
Ligand Pharmaceuticals	$274.48M	21.63	$124.45M	$7.37	40.20

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 55.95% compared to ANI Pharmaceuticals' net margin of 9.98%. ANI Pharmaceuticals' return on equity of 27.51% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	9.98%	27.51%	10.02%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

ANI Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

ANI Pharmaceuticals currently has a consensus target price of $105.00, suggesting a potential upside of 29.57%. Ligand Pharmaceuticals has a consensus target price of $319.00, suggesting a potential upside of 7.67%. Given ANI Pharmaceuticals' higher possible upside, equities analysts clearly believe ANI Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Ligand Pharmaceuticals beats ANI Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

In the previous week, Incyte had 26 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 38 mentions for Incyte and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat Incyte's score of 1.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	21 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has a net margin of 55.95% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	26.71%	26.66%	19.77%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

Incyte currently has a consensus target price of $112.85, suggesting a potential downside of 13.15%. Ligand Pharmaceuticals has a consensus target price of $319.00, suggesting a potential upside of 7.67%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ligand Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	14 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.36
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

97.0% of Incyte shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Incyte has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Incyte has higher revenue and earnings than Ligand Pharmaceuticals. Incyte is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	5.05	$1.29B	$7.08	18.35
Ligand Pharmaceuticals	$274.48M	21.63	$124.45M	$7.37	40.20

Summary

Incyte and Ligand Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, United Therapeutics had 20 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 32 mentions for United Therapeutics and 12 mentions for Ligand Pharmaceuticals. United Therapeutics' average media sentiment score of 1.25 beat Ligand Pharmaceuticals' score of 1.07 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	23 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has a net margin of 55.95% compared to United Therapeutics' net margin of 40.62%. United Therapeutics' return on equity of 19.24% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	40.62%	19.24%	17.25%
Ligand Pharmaceuticals	55.95%	16.19%	11.13%

United Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.98	$1.33B	$27.09	19.33
Ligand Pharmaceuticals	$274.48M	21.63	$124.45M	$7.37	40.20

United Therapeutics presently has a consensus price target of $648.33, indicating a potential upside of 23.82%. Ligand Pharmaceuticals has a consensus price target of $319.00, indicating a potential upside of 7.67%. Given United Therapeutics' higher possible upside, equities analysts clearly believe United Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

United Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

United Therapeutics beats Ligand Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Ligand Pharmaceuticals (NASDAQ:LGND) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

In the previous week, Neurocrine Biosciences had 9 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 12 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.07 beat Neurocrine Biosciences' score of 1.04 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	11 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has higher revenue and earnings than Ligand Pharmaceuticals. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$274.48M	21.63	$124.45M	$7.37	40.20
Neurocrine Biosciences	$3.10B	5.93	$478.60M	$6.49	28.17

Ligand Pharmaceuticals has a net margin of 55.95% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Neurocrine Biosciences	21.55%	19.79%	13.82%

Ligand Pharmaceuticals has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Ligand Pharmaceuticals presently has a consensus target price of $319.00, indicating a potential upside of 7.67%. Neurocrine Biosciences has a consensus target price of $194.05, indicating a potential upside of 6.14%. Given Ligand Pharmaceuticals' higher possible upside, research analysts clearly believe Ligand Pharmaceuticals is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Neurocrine Biosciences	0 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.96

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ligand Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LGND vs. The Competition

Export

Metric	Ligand Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.96B	$3.68B	$6.95B	$12.19B
Dividend Yield	N/A	2.17%	2.66%	8.55%
P/E Ratio	40.20	21.89	27.27	23.75
Price / Sales	21.63	296.38	520.40	88.01
Price / Cash	37.89	153.52	49.60	59.05
Price / Book	5.73	7.94	10.24	6.06
Net Income	$124.45M	$23.81M	$3.60B	$336.44M
7 Day Performance	-3.01%	-3.95%	-1.80%	-2.14%
1 Month Performance	-2.41%	-4.65%	-2.67%	-3.32%
1 Year Performance	119.60%	32.78%	18.21%	13.49%

Ligand Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LGND Ligand Pharmaceuticals	4.1175 of 5 stars	$296.28 -0.4%	$319.00 +7.7%	+119.0%	$5.96B	$274.48M	40.20	80	Positive News
ADMA ADMA Biologics	4.6821 of 5 stars	$8.27 -1.2%	$18.67 +125.7%	-52.9%	$1.92B	$509.86M	12.16	530	Trending News
ANIP ANI Pharmaceuticals	4.4023 of 5 stars	$77.65 -1.1%	$105.00 +35.2%	+16.1%	$1.77B	$883.37M	19.66	600	Positive News
INCY Incyte	3.3606 of 5 stars	$117.67 +0.8%	$111.10 -5.6%	+69.3%	$23.51B	$5.14B	16.62	2,844	Trending News Earnings Report Analyst Forecast
UTHR United Therapeutics	4.7163 of 5 stars	$528.47 -0.2%	$648.33 +22.7%	+73.4%	$22.43B	$3.17B	19.51	1,400	Positive News Upcoming Earnings Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LGND) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, INCY, UTHR, and NBIX

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Ligand Pharmaceuticals compare to Incyte?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ligand Pharmaceuticals (LGND) Competitors

LGND vs. ADMA, ANIP, INCY, UTHR, and NBIX

How does Ligand Pharmaceuticals compare to ADMA Biologics?

Does the media prefer LGND or ADMA?

Which has more risk and volatility, LGND or ADMA?

Do insiders and institutionals have more ownership in LGND or ADMA?

Is LGND or ADMA more profitable?

Which has better valuation & earnings, LGND or ADMA?

Do analysts prefer LGND or ADMA?

Summary

How does Ligand Pharmaceuticals compare to ANI Pharmaceuticals?

Does the media favor ANIP or LGND?

Which has stronger valuation & earnings, ANIP or LGND?

Do insiders and institutionals hold more shares of ANIP or LGND?

Is ANIP or LGND more profitable?

Which has more volatility and risk, ANIP or LGND?

Do analysts prefer ANIP or LGND?

Summary

How does Ligand Pharmaceuticals compare to Incyte?

Does the media favor INCY or LGND?

Is INCY or LGND more profitable?

Do analysts prefer INCY or LGND?

Do insiders and institutionals believe in INCY or LGND?

Which has more risk and volatility, INCY or LGND?

Which has stronger earnings & valuation, INCY or LGND?

Summary

How does Ligand Pharmaceuticals compare to United Therapeutics?

Does the media favor UTHR or LGND?

Do insiders and institutionals have more ownership in UTHR or LGND?

Is UTHR or LGND more profitable?

Which has higher earnings and valuation, UTHR or LGND?

Do analysts recommend UTHR or LGND?

Which has more volatility and risk, UTHR or LGND?

Summary

How does Ligand Pharmaceuticals compare to Neurocrine Biosciences?

Does the media favor LGND or NBIX?

Which has higher earnings and valuation, LGND or NBIX?

Is LGND or NBIX more profitable?

Which has more volatility and risk, LGND or NBIX?

Do analysts prefer LGND or NBIX?

Do institutionals & insiders have more ownership in LGND or NBIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND vs. The Competition

Ligand Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools